Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Whole-Genome MRD Test Detects Traces of Cancer During and After Treatment

By LabMedica International staff writers
Posted on 26 Oct 2026

Small amounts of cancer can remain after treatment at levels that are difficult to detect, creating uncertainty about recurrence risk. More...

Molecular residual disease (MRD) testing addresses this challenge by searching blood for circulating tumor DNA to provide information about treatment response and surveillance. Building on this approach, a newly launched test combines tumor-informed whole-genome sequencing with targeted DNA enrichment to detect cancer signals below one part per million when higher DNA inputs are available.

Abbott has announced the commercial availability of its next-generation Oncodetect MRD test for patients with solid tumors. The test uses tumor tissue, typically obtained through biopsy or surgery, to identify DNA changes unique to each cancer and create a molecular fingerprint. Blood samples are then analyzed for the same tumor-specific signals, allowing subsequent draws to track changes in circulating tumor DNA over time. Oncodetect combines whole-genome sequencing with MAESTRO (minor allele enriched sequencing through recognition oligonucleotides) technology.

Whole-genome sequencing enables Oncodetect to track up to 5,000 patient-specific variants, compared with up to 200 in the first-generation assay. MAESTRO technology further enhances sensitivity by enriching tumor DNA from blood by up to approximately 1,000-fold before sequencing. Under high-end input conditions, the assay has a limit of detection below one part per million, representing a 30-fold improvement, while maintaining greater than 99% analytical specificity.

The test was developed, and its performance characteristics determined, by Genomic Health. It has not been cleared or approved by the U.S. Food and Drug Administration (FDA). The Genomic Health laboratory performing the assay is certified under CLIA regulations and qualified to perform high-complexity testing.

Clinical studies are evaluating the test across multiple solid tumor types. In locally advanced esophageal cancer, longitudinal testing detected circulating tumor DNA before recurrence in all 14 patients who experienced recurrence, corresponding to 100% sensitivity. In the PARTNER study of triple-negative breast cancer, a single post-surgery blood draw identified 90% of patients who developed distant recurrence within five years, representing a three-fold improvement over the first-generation test. In patients with stage II–IV colorectal cancer, Beta-CORRECT data showed a 30% absolute improvement in sensitivity for detecting recurrence within two years at a single post-surgical time point.

Oncodetect must be ordered by a healthcare provider and is integrated into leading electronic health record systems to support test ordering and results access within existing clinical workflows. More than 20 ongoing studies are evaluating the assay across tumor types, alongside academic collaborations and real-world research. Abbott is also working to expand payor coverage and international access.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Drug Testing Assays
Atellica DT 250 Analyzer
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.